Fig. 1: Overview of the subject and data sets.
From: A roadmap to the molecular human linking multiomics with population traits and diabetes subtypes
A Study cohort and collected samples; B Data and omics platforms used for data generation; C Calculation strategies used to define: Within platform significant associations GGM—(Gaussian Graphical Model); Between platform significant associations MBH—(Mutual best hit); Multiomics GWAS—(Genome-wide association studies); Multiomics EWAS—(Epigenome-wide association studies); and Multiomics TWAS—(Transcriptome-wide association studies); as well as statistical associations between each platform and the phenotype such as SEX, AGE, type 2 diabetes (T2D) and body mass index (BMI). CLIN clinical chemistry parameters, DNA genotype data, MET DNA methylation sites, RNA RNA transcripts determined with RNA-sequencing, miRNA microRNA profiles, SOMA blood circulating proteins measured with aptamer-based technology (SomaLogic), OLINK blood circulating proteins measured using high-multiplex immunoassays (Olink), PGP glycan traits N-glycosylation, IgG IgG-glycopepdides, IgA IgA and IgG-glycopeptides BRAIN plasma lipoproteins, LD plasma lipids quantified using Lipidyzer, BM plasma lipids quantified with Biocrates p150 kit, HDF plasma metabolic traits profiled on HD4 platform (Metabolon), PM plasma metabolic traits profiled on HD2 platform (Metabolon), SM saliva metabolic traits profiled on HD2 platform (Metabolon), UM urine metabolic traits profiled on HD2 platform (Metabolon), CM urine metabolites quantified with 1H NMR deploying Chenomx. N number of subjects, F female, B blood, U urine, S saliva. The source data for (C) is available in the Supplementary Data (SD) 2−9 and 11−14.
